About AnnieGuard
At AnnieGuard, we are redefining how the world understands and detects rare diseases.
We collaborate with independent research organizations, health networks, and clinical partners across emerging and underrepresented regions to advance early detection, improve diagnostic precision, and uncover new biological insights.
Our mission is to transform rare-disease care through ethical, intelligent discovery—saving time, reducing misdiagnosis, and improving outcomes for patients too often overlooked.
Affiliations & Strategic Partnerships
A globally anchored company built on U.S. research infrastructure, international rare-disease alliances, and UK commercialization pathways.
AnnieGuard’s work is strengthened by partners across state innovation agencies, research ecosystems, global advocacy networks, and national healthtech organizations. These affiliations support our mission to accelerate rare-disease detection, precision oncology insights, and clinical impact worldwide.
U.S. R&D Foundation
Global Rare-Disease Network
Home to AnnieGuard’s innovation origin — supported through Maryland’s state-backed technology ecosystem and bwtech@UMBC’s research infrastructure.
Our collaboration with SPAGN as a Pharma Partner strengthens AnnieGuard’s patient-centered innovation and global advocacy reach.
NHS Innovation Collaborations
Innovation Networks
AnnieGuard is an active member of the Maryland Tech Council, connecting with technology and life-science leaders across the region to strengthen innovation, partnerships, and growth across Maryland’s STEM ecosystem.
AnnieGuard participates in the Arden & Greater East Midlands Cancer Alliance’s cross-industry innovation programme, contributing computational analytics to accelerate early cancer detection, strengthen trial-eligibility identification, and support next-phase NHS transformation initiatives.
UK HealthTech Commercialization
As a member of ABHI, AnnieGuard is aligned with the UK’s leading pathway for healthtech adoption and NHS integration.
Our Capabilities
At AnnieGuard, our capabilities span the full spectrum of rare-disease intelligence — from early detection to data-driven treatment insights. We build systems that bridge the gap between biology and technology, empowering partners worldwide to make faster, more accurate clinical decisions and uncover breakthroughs hidden in data.
Strategic Partnerships & Consulting
Through selective collaborations with life-science consultancies and innovation networks, we extend AnnieGuard’s impact globally—tailoring our solutions to align with regional priorities and institutional goals.
Pharma & Life Science Analytics
We collaborate with pharmaceutical and life-science partners to extract meaningful insights from complex biological datasets—revealing patterns and opportunities that enhance research precision and innovation.
Philosophy
Our philosophy is rooted in Biological-First Intelligence — the conviction that true innovation in healthcare begins with the biology itself. We start where disease starts: within the body’s molecular and clinical signals.
By aligning intelligent analytics with biological understanding, AnnieGuard goes beyond conventional AI—revealing insights that drive earlier detection, more precise care, and deeper trust between patients, clinicians, and technology.
Contact
Get in Touch
Have a question or want to explore how AnnieGuard’s Biological-First Intelligence can support your organization’s goals?
Reach out to us to learn more about our technology, partnerships, or upcoming collaborations in rare-disease innovation.
​